WCM
ESPR

Weld Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Weld Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-19,725
Closed -$733K – 529
2020
Q3 		$733K Buy
19,725
+10,992
+126% +$435K 0.29% 106
2020
Q2 		$448K Buy
+8,733
New +$365K 0.18% 202
2019
Q4 		– Sell
-7,942
Closed -$291K – 698
2019
Q3 		$291K Buy
+7,942
New +$315K 0.05% 573

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Weld Capital Management's ESPR Position: Q4 2020 in Review

Weld Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2020, closing a stake of 19,725 shares — an estimated $733K sold.

Weld Capital Management first reported a position in ESPR in Q3 2019 and held it in 3 quarters. The position peaked at $733K in Q3 2020. 157 funds tracked by Wall St. Rank hold ESPR as of Q4 2020.

  • Weld Capital Management reported no remaining Esperion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Weld Capital Management sold 19,725 Esperion Therapeutics shares in Q4 2020, an estimated $733K.
  • Weld Capital Management first reported a position in Esperion Therapeutics in Q3 2019 and held it in 3 quarters.
  • Weld Capital Management's Esperion Therapeutics position peaked at $733K in Q3 2020.
  • 157 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2020.

Based on Weld Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.